for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

テバ・ファーマシューティカル・インダストリーズ

TEVA.N

現在値

8.62USD

変化

-0.08(-0.86%)

出来高

814,721

本日のレンジ

8.60

 - 

8.90

52週レンジ

8.24

 - 

13.29

∙ 約20分前の相場を表示しています。

適時開示

Teva And MedinCell Announce FDA Acceptance Of New Drug Application For TV-46000/mdc-IRM As A Treatment For Patients With Schizophrenia

Aug 31 (Reuters) - Medincell SA <MEDCL.PA>::TEVA AND MEDINCELL ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR TV-46000/MDC-IRM AS A TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA.

Teva Announces Post HOC Analysis Of Long-Term Data Examining Treatment With Austedo® (Deutetrabenazine) Tablets In Adult Patients With Tardive Dyskinesia

Aug 20 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA ANNOUNCES POST HOC ANALYSIS OF LONG-TERM DATA EXAMINING TREATMENT WITH AUSTEDO® (DEUTETRABENAZINE) TABLETS IN ADULT PATIENTS WITH TARDIVE DYSKINESIA.TEVA PHARMACEUTICAL INDUSTRIES LTD - SAFETY PROFILE OF AUSTEDO WAS GENERALLY SIMILAR ACROSS BOTH YOUNGER AND OLDER PATIENTS.TEVA PHARMACEUTICAL INDUSTRIES - DUE TO UNCONTROLLED NATURE OF DATA AND POST HOC ANALYSIS, NO DETERMINATION OF STATISTICAL SIGNIFICANCE CAN BE MADE.

Teva Reports Second Quarter 2021 Financial Results

July 28 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS.Q2 NON-GAAP EARNINGS PER SHARE $0.59.Q2 GAAP EARNINGS PER SHARE $0.19.Q2 REVENUE ROSE 1 PERCENT TO $3.91 BILLION.SEES 2021 NET REVENUES OF $16.0 - $16.4 BILLION.2021 REVENUE OUTLOOK REVISED LOWER TO REFLECT ONGOING IMPACT OF COVID-19.COPAXONE REVENUES IN OUR NORTH AMERICA SEGMENT IN Q2 OF 2021 DECREASED BY 36% TO $152 MILLION.TEVA PHARMACEUTICAL - GENERIC PRODUCTS REVENUES IN OUR NORTH AMERICA SEGMENT (INCLUDING BIOSIMILARS) IN Q2 OF 2021 WERE $951 MILLION, AN INCREASE OF 3%.AS OF JUNE 30, 2021, DEBT WAS $25,132 MILLION, COMPARED TO $24,986 MILLION AS OF MARCH 31, 2021.

Formycon Announces Conclusion Of Agreement Between Bioeq And Teva

June 28 (Reuters) - FORMYCON AG <FYB.DE>::ANNOUNCES CONCLUSION OF EXCLUSIVE COMMERCIALIZATION AGREEMENT BETWEEN BIOEQ AG AND TEVA PHARMACEUTICAL INDUSTRIES LTD. FOR FYB201 IN EUROPE, CANADA, ISRAEL AND NEW ZEALAND.SUBMISSION OF MARKETING AUTHORIZATION FOR FYB201 TO EUROPEAN MEDICINES AGENCY (EMA) IS EXPECTED TO TAKE PLACE CONTEMPORARILY.

Teva And Bioeq Announce Commercial Partnership For Biosimilar

June 28 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA AND BIOEQ ANNOUNCE COMMERCIAL PARTNERSHIP FOR BIOSIMILAR.TEVA - AGREEMENT INCLUDES COMMERCIALIZING BIOSIMILAR CANDIDATE OF OPHTHALMOLOGY DRUG RANIBIZUMAB IN EUROPE, CANADA, ISRAEL, GLOBAL MARKETS.TEVA PHARMACEUTICAL INDUSTRIES LTD - ENTERED INTO A STRATEGIC PARTNERSHIP FOR EXCLUSIVE COMMERCIALIZATION OF BIOEQ'S FYB201.TEVA PHARMACEUTICAL INDUSTRIES LTD - BIOEQ WILL BE RESPONSIBLE FOR DEVELOPMENT, REGISTRATION AND SUPPLY OF BIOSIMILAR.TEVA PHARMACEUTICAL INDUSTRIES LTD - TEVA AND BIOEQ WILL SHARE REVENUE FROM COMMERCIALIZATION OF BIOSIMILAR..TEVA PHARMACEUTICAL INDUSTRIES LTD - ALL OTHER FINANCIAL TERMS AND PRODUCT DETAILS REMAIN CONFIDENTIAL..

Exelixis Says In May, Got Notice Letters From Teva Regarding ANDA Teva Submitted To FDA

June 21 (Reuters) - Exelixis Inc <EXEL.O>::EXELIXIS- IN MAY, GOT NOTICE LETTERS FROM TEVA REGARDING ANDA TEVA SUBMITTED TO FDA, REQUESTING APPROVAL TO MARKET GENERIC VERSION OF CABOMETYX TABLETS.EXELIXIS INC - ON JUNE 17, FILED COMPLAINT IN UNITED STATES DISTRICT COURT FOR DISTRICT OF DELAWARE FOR PATENT INFRINGEMENT AGAINST TEVA.EXELIXIS INC - TEVA'S NOTICE LETTERS INCLUDED PARAGRAPH IV CERTIFICATIONS WITH RESPECT TO OUR U.S. PATENT NOS. 9,724,342 AND 10,034,873.EXELIXIS INC - TEVA'S NOTICE LETTERS DID NOT PROVIDE NOTICE OF A PARAGRAPH IV CERTIFICATION AGAINST ANY ADDITIONAL CABOMETYX PATENTS.EXELIXIS INC - EXELIXIS IS SEEKING EQUITABLE RELIEF ENJOINING TEVA FROM INFRINGING PATENTS.EXELIXIS - SEEKING ORDER THAT EFFECTIVE DATE OF ANY FDA APPROVAL OF TEVA’S ANDA BE NO EARLIER THAN EXPIRATION OF ALL OF EXELIXIS' 3 U.S. PATENTS.

Teva Reports Q1 EPS Of $0.07

April 28 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.63.Q1 GAAP EARNINGS PER SHARE $0.07.Q1 REVENUE FELL 9 PERCENT TO $3.982 BILLION.FULL YEAR 2021 BUSINESS OUTLOOK REAFFIRMED.IN Q1 OF 2021, WE RECOGNIZED A GAAP TAX EXPENSE OF $62 MILLION, ON PRE-TAX INCOME OF $144 MILLION.AS OF MARCH 31, 2021, DEBT WAS $24,986 MILLION VERSUS $25,919 MILLION AS OF DECEMBER 31, 2020.TEVA - NON-GAAP NET INCOME AND NON-GAAP EPS FOR Q1 OF 2021 WERE ADJUSTED TO EXCLUDE AMORTIZATION OF PURCHASED INTANGIBLE ASSETS OF $242 MILLION.TEVA PHARMACEUTICAL - REVENUES FROM OU NORTH AMERICA SEGMENT IN Q1 OF 2021 WERE $1,989 MILLION, A DECREASE OF $94 MILLION, OR 5%, COMPARED TO Q1 OF 2020.TEVA - GENERIC PRODUCTS REVENUE IN NORTH AMERICA SEGMENT (INCLUDING BIOSIMILARS) IN Q1 OF 2021 WERE $1,053 MILLION, AN INCREASE OF 11%.COPAXONE REVENUES IN OUR NORTH AMERICA SEGMENT IN Q1 OF 2021 DECREASED BY 17% TO $164 MILLION.

Teva Pharmaceutical Industries Says 2020 Total Compensation For CEO Kåre Schultz $15.7 Million

April 21 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA PHARMACEUTICAL INDUSTRIES - 2020 TOTAL COMPENSATION FOR CEO KÅRE SCHULTZ $15.7 MILLION VERSUS $11.6 MILLION IN 2019.TEVA PHARMACEUTICAL - 2020 RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO THAT OF ANNUAL TOTAL COMPENSATION OF MEDIAN EMPLOYEE WAS 220 TO 1.

Teva Pharmaceutical Industries Limited Reports A Passive Stake Of 5.3% In American Well Corp As Of Dec 31, 2020 - SEC Filing

Feb 11 (Reuters) - American Well Corp <AMWL.N>::TEVA PHARMACEUTICAL INDUSTRIES LIMITED REPORTS A PASSIVE STAKE OF 5.3% IN AMERICAN WELL CORP AS OF DEC 31, 2020 - SEC FILING.

Teva Pharmaceutical Industries Posts Q4 Revenue $4.454 Billion

Feb 10 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS.Q4 REVENUE $4.454 BILLION.2021 REVENUES ARE EXPECTED TO BE $16.4 - $16.8 BILLION.2021 NON-GAAP EPS IS EXPECTED TO BE $2.50 - $2.70.QTRLY NON-GAAP EPS $0.68.QTRLY EARNINGS PER SHARE $0.14.COPAXONE REVENUES IN EUROPE SEGMENT IN Q4 OF 2020 WERE $106 MILLION, FLAT COMPARED Q4 2019.TEVA PHARMACEUTICAL INDUSTRIES - GENERIC PRODUCTS REVENUE IN OUR NORTH AMERICA SEGMENT IN Q4 INCREASED BY 6% TO $1,206 MILLION.TEVA PHARMACEUTICAL INDUSTRIES - COPAXONE REVENUE IN OUR NORTH AMERICA SEGMENT IN Q4 DECREASED BY 19% TO $213 MILLION.AS OF DECEMBER 31, 2020, DEBT WAS $25,919 MILLION VERSUS $26,908 MILLION AS OF DECEMBER 31, 2019.FY2021 EARNINGS PER SHARE VIEW $2.67, REVENUE VIEW $16.75 BILLION -- REFINITIV IBES DATA.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up